GlassScriptPhysician profile
Timothy P Lax
NPI 1487810156
$1,856.41
in general payments reported to CMS, 2019-2025
20 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $254 · 2024: $662 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.89 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $458.55 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Csl Behring | $220.51 | 2023-2025 | Haegarda, Andembry, Hizentra |
| Pharming Healthcare, INC. | $159.45 | 2023-2025 | Ruconest |
| Gc Biopharma USA, INC. | $106.66 | 2024-2025 | Alyglo, Alyglo |
| Dermavant Sciences, INC. | $105.32 | 2024 | Vtama |
| Genzyme Corporation | $104.72 | 2025 | |
| Amgen INC. | $102.33 | 2023-2025 | Tezspire |
| Kaleo, INC. | $102.18 | 2023-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $85.40 | 2023-2025 | Cuvitru, Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $63.45 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $58.73 | 2023-2024 | Nucala, Trelegy Ellipta |
| Pfizer INC. | $55.42 | 2023-2025 | |
| Galderma Laboratories, L.P. | $51.11 | 2025 | Nemluvio |
| Ionis Pharmaceuticals, INC. | $45.53 | 2025 | Dawnzera |
| Genentech USA, INC. | $32.43 | 2025 | Xolair |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $29.96 | 2025 | |
| Grifols USA, LLC | $20.81 | 2025 | Prolastin-C Liquid |
| Cycle Pharmaceuticals INC | $19.95 | 2025 | Sajazir |
| Novartis Pharmaceuticals Corporation | $17.55 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.35 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.